Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AstraZeneca PLC
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The US biotech’s lead candidate missed the mark in a Phase III hospital-related pneumonia trial due to low recruitment affected by macroeconomic headwinds but analysts retain high hopes for another upcoming study.
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
- Other Names / Subsidiaries
- Alexion Pharmaceuticals Inc.
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Cellective Therapeutics, Inc.
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Neogene Therapeutics, Inc.
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- TeneoTwo, Inc.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.